Basics Ocular Therapeutix, Inc. Ocular Therapeutix Inc is a biopharmaceutical company. It is engaged in developing and commercializing therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. IPO Date: July 25, 2014 Sector: Healthcare Industry: Biotech Market Cap: $2.37B Activated in VL: True Average Daily Range Avg Daily Range: $0.27 | 3.20% Avg Daily Range (30 D): $0.30 | 2.49% Avg Daily Range (90 D): $0.25 | 2.57% Institutional Daily Volume Avg Daily Volume: .78M Avg Daily Volume (30 D): 1.9M Avg Daily Volume (90 D): 1.78M Trade Size Avg Trade Size (Sh.): 134 Avg Trade Size (Sh.) (30 D): 86 Avg Trade Size (Sh.) (90 D): 98 Institutional Trades Total Inst.Trades: 1,183 Avg Inst. Trade: $1.82M Avg Inst. Trade (30 D): $2.24M Avg Inst. Trade (90 D): $2.79M Avg Inst. Trade Volume: .19M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.85M Avg Closing Trade (30 D): $3.04M Avg Closing Trade (90 D): $2.79M Avg Closing Volume: 198.52K     News Aug 6, 2025 @ 1:12 AM OCUL Sales Drop 18% Source: Jesterai Jun 16, 2025 @ 11:00 AM Ocular Therapeutixâ„¢ to Participate in Clinic... Source: N/A Mar 31, 2025 @ 11:00 AM Ocular Therapeutixâ„¢ to Participate in Two In... Source: N/A Jan 17, 2025 @ 12:00 PM Ocular Therapeutixâ„¢ Reports Inducement Grant... Source: Ocular Therapeutix, Inc. Jun 14, 2024 @ 12:01 PM Deep Dive Into Ocular Therapeutix Stock: Analyst P... Source: Benzinga Insights Financials   TTM Q1 2025 Q3 2024 Basic EPS $-.39 $-.38 $-.22 Diluted EPS $-.39 $-.38 $-.22 Revenue $ 13.46M $ 10.7M $ 15.43M Gross Profit $ 11.52M $ 9.44M $ 13.86M Net Income / Loss $ -67.81M $ -64.05M $ -36.49M Operating Income / Loss $ -67.64M $ -63.92M $ -46M Cost of Revenue $ 1.94M $ 1.26M $ 1.56M Net Cash Flow $ 41.45M $ -42.42M $ -32.47M PE Ratio